FB-1002(Frontier Biotechnologies)

N/A

Report date: 2022/06/22 17:46:29

Base Information

Drug NameFB-1002(Frontier Biotechnologies)
Drug Alias NameAlbuvirtide/3BNC-117FB-1002(前沿生物)
ClassificationSmall molecules
Mechanisms of ActionTransmembrane glycoprotein gp41 inhibitorsHIV fusion inhibitorsHIV envelope protein gp120 modulators
TargetsTransmembrane glycoprotein gp41HIV envelope protein gp120
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes AlbuvirtideTeropavimab
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesFrontier Biotechnologies IncShanghai Institute Of Materia Medica, Chinese Academy Of Sciences
China Registration ClassN/A

Develop Information

Active CompaniesFrontier Biotechnologies Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A